Evaluation of harm in the pharmacotherapy of irritable bowel syndrome

American Journal of Medicine

Volumn 125, Issue 4, 2012, Pages 381-393

  Shah, Eric ^a   Kim, Sharon ^b   Chong, Kelly ^c   Lembo, Anthony ^d   Pimentel, Mark ^b  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER SCHOOL OF MEDICINE   (United States)

^b CEDARS SINAI MEDICAL CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Alosetron; Irritable bowel syndrome; Lubiprostone; Rifaximin; Serotonin reuptake inhibitors; Tricyclic antidepressants

Indexed keywords

ALOSETRON; AMITRIPTYLINE; CITALOPRAM; DESIPRAMINE; DOXEPIN; FLUOXETINE; LUBIPROSTONE; PAROXETINE; PLACEBO; RIFAXIMIN; SEROTONIN 3 AGONIST; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ANXIETY; ARTICLE; BLURRED VISION; COLON DISEASE; CONSTIPATION; DECREASED APPETITE; DIARRHEA; DIZZINESS; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPHORIA; EYE TOXICITY; FATIGUE; FLATULENCE; FLUSHING; HEADACHE; HEART PALPITATION; HEART VENTRICLE EXTRASYSTOLE; HEMORRHOID; HUMAN; INSOMNIA; IRRITABLE COLON; ISCHEMIC COLITIS; META ANALYSIS; NAUSEA; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; REPRODUCTIVE TOXICITY; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SIDE EFFECT; SYSTEMATIC REVIEW; TACHYCARDIA; TASTE DISORDER; TREATMENT OUTCOME; VIRUS INFECTION; VOMITING; XEROSTOMIA;

EID: 84858958766     PISSN: 00029343     EISSN: 15557162     Source Type: Journal    
DOI: 10.1016/j.amjmed.2011.08.026     Document Type: Review

References (46)

1. Saito YA, Schoenfeld P, Locke GR 3rd. The epidemiology of irritable bowel syndrome in North America: a systematic review. Am J Gastroenterol. 2002;97:1910-1915.
2. Longstreth GF. Definition and classification of irritable bowel syndrome: current consensus and controversies. Gastroenterol Clin N. 2005;34:173-187. (Pubitemid 40615949)
3. Ersryd A, Posserud I, Abrahamsson H, et al. Subtyping the irritable bowel syndrome by predominant bowel habit: Rome II versus Rome III. Aliment Pharmacol Ther. 2007;26:953-961. (Pubitemid 47346699)
4. Heaton KW, O'Donnell LJ. An office guide to whole-gut transit time. Patients' recollection of their stool form. J Clin Gastroenterol. 1994; 19:28-30. (Pubitemid 24222236)
5. Longstreth GF, Thompson WG, Chey WD, et al. Functional bowel disorders. Gastroenterology. 2006;130:1480-1491.
6. Delvaux M. Role of visceral sensitivity in the pathophysiology of irritable bowel syndrome. Gut. 2002;51(Suppl 1):67-71.
7. Camilleri M. Serotonin in the gastrointestinal tract. Curr Opin Endocrinol Diabetes Obes. 2009;16:53-59.
8. Collins SM, Denou E, Verdu EF, et al. The putative role of the intestinal microbiota in irritable bowel syndrome. Digest Liver Dis. 2009;41:850-853.
9. American College of Gastroenterology Task Force on Irritable Bowel Syndrome, Brandt LJ, Chey WD, et al. An evidence-based position statement on the management of irritable bowel syndrome. Am J Gastroenterol. 2009;104(Suppl 1):S1-S35.
10. Ford AC, Brandt LJ, Young C, et al. Efficacy of 5-HT 3 antagonists and 5-HT 4 agonists in irritable bowel syndrome: systematic review and meta-analysis. Am J Gastroenterol. 2009;104:1831-1843.
11. Ford AC, Talley NJ, Schoenfeld PS, et al. Efficacy of antidepressants and psychological therapies in irritable bowel syndrome: systematic review and meta-analysis. Gut. 2009;58:367-378.
12. Menees SB, Maneerattanaporn M, Chey WD. Efficacy of rifaximin in patients with irritable bowel syndrome: a meta analysis. Gastroenterology. 2011;215:A54.
13. Spiegel BM. Questioning the bacterial overgrowth hypothesis of IBS: an epidemiologic and evolutionary perspective. Clin Gastroenterol H. 2011 Mar 10. [Epub ahead of print].
14. Moher D, Liberati A, Tetzlaff J, et al. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement. Ann Intern Med. 2009;151:264-269.
15. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177-188. (Pubitemid 17189972)
16. Hulley SB, Cummings SR, Browner WS, et al. Designing Clinical Research. In: Seigafuse S, Winter N, eds. Utilizing Existing Databases. 3rd ed. Philadelphia, PA: Lippincott, Williams, & Wilkins; 2007:220.
17. Sweeting MJ, Sutton AJ, Lambert PC. What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data. Stat Med. 2004;23:1351-1375. (Pubitemid 38594143)
18. Harbord R M, Egger M, Sterne JAC. A modified test for small-study effects in meta-analysis of controlled clinical trials with binary endpoints. Stat Med. 2006;25:3443-3457. (Pubitemid 44575162)
19. Boerner D, Eberhardt R, Metz K, et al. Wirksamkeit und vertraglichkeit eines antidepressivuns beim colon irritabile. Therapiewoche. 1988;38:201-208.
20. Bergmann M, Heddergott A, Schlosser T. Die therapie des colon irritabile mit trimipramin (Herphonal) - Eine kontrollierte studie. Z Klin Med. 1991;46:1621-1628.
21. Drossman DA, Toner BB, Whitehead WE, et al. Cognitive-behavioral therapy versus education and desipramine versus placebo for moderate to severe functional bowel disorders. Gastroenterology. 2003;125:19-31. (Pubitemid 36799103)
22. Heefner JD, Wilder RM, Wilson ID. Irritable colon and depression. Psychosomatics. 1978;19:540-547. (Pubitemid 9068233)
23. Myren J, Groth H, Larssen SE, et al. The effect of trimipramine in patients with the irritable bowel syndrome: a double-blind study. Scand J Gastroenterol. 1982;17:871-875. (Pubitemid 12032572)
24. Nigam P, Kapoor KK, Rastog CK, et al. Different therapeutic regimens in irritable bowel syndrome. J Assoc Physicians India. 1984;32:1041-1044.
25. Talley NJ, Kellow JE, Boyce P, et al. Antidepressant therapy (imipramine and citalopram) for irritable bowel syndrome: a double-blind, randomized, placebo-controlled trial. Digest Dis Sci. 2008;53:108-115. (Pubitemid 350265657)
26. Vahedi H, Merat S, Momtahen S, et al. Clinical trial: the effect of amitriptyline in patients with diarrhea-predominant irritable bowel syndrome. Aliment Pharmacol Ther. 2008;27:678-684. (Pubitemid 351406307)
27. Vij JC, Jiloha RC, Kumar N, et al. Effect of antidepressant drug (doxepin) on irritable bowel syndrome patients. Indian J Psychiatry. 1991;33:243-246.
28. Bardhan KD, Bodemar G, Geldof H, et al. A double-blind, randomized, placebo-controlled dose-ranging study to evaluate the efficacy of alosetron in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther. 2000;14:23-34. (Pubitemid 30058157)
29. Camilleri M, Mayer EA, Drossman DA, et al. Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5-HT3 receptor antagonist. Aliment Pharmacol Ther. 1999;13:1149-1159. (Pubitemid 29445893)
30. Camilleri M, Northcutt AR, Kong S, et al. Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial. Lancet. 2000;355:1035-1040. (Pubitemid 30162805)
31. Camilleri M, Chey WY, Mayer EA, et al. A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome. Arch Intern Med. 2001;161:1733-1740. (Pubitemid 32679548)
32. Chang L, Ameen VZ, Dukes GE, et al. A dose-ranging, phase II study of the efficacy and safety of alosetron in men with diarrhea-predominant IBS. Am J Gastroenterol. 2005;100:115-123. (Pubitemid 41623278)
33. Krause R, Ameen V, Gordon SH, et al. A randomized, double-blind, placebo-controlled study to assess efficacy and safety of 0.5 mg and 1 mg alosetron in women with severe diarrhea-predominant IBS. Am J Gastroenterol. 2007;102:1709-1719. (Pubitemid 47206697)
34. Chey WD, Chey WY, Heath AT, et al. Long-term safety and efficacy of alosetron in women with severe diarrhea-predominant irritable bowel syndrome. Am J Gastroenterol. 2004;99:2195-2203. (Pubitemid 39524711)
35. Lembo T, Wright RA, Bagby B, et al., Lotronex Investigator Team. Alosetron controls bowel urgency and provides global symptom improvement in women with diarrhea-predominant irritable bowel syndrome. Am J Gastroenterol. 2001;96:2662-2670.
36. Sharara AI, Aoun E, Abdul-Baki H, et al. A randomized double-blind placebo-controlled trial of rifaximin in patients with abdominal bloating and flatulence. Am J Gastroenterol. 2006;101:326-333. (Pubitemid 43381675)
37. Pimentel M, Park S, Mirocha J, et al. The effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome. Ann Intern Med. 2006;145:557-563. (Pubitemid 46780934)
38. Pimentel M, Lembo A, Chey WD, et al. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med. 2011;364:22-32.
39. Lembo A, Zakko SF, Ferreira NL, et al. Rifaximin for the treatment of diarrhea-associated irritable bowel syndrome: short term treatment leading to long term sustained response. Gastroenterology. 2008;134: A545.
40. Tabas G, Beaves M, Wang J, et al. Paroxetine to treat irritable bowel syndrome not responding to high fiber diet: a double-blind placebo-controlled trial. Am J Gastroenterol. 2004;99:914-920. (Pubitemid 39090223)
41. Tack J, Broekaert D, Fischler B, et al. A controlled crossover study of the selective serotonin reuptake inhibitor citalopram in irritable bowel syndrome. Gut. 2006;55:1095-1103. (Pubitemid 44085674)
42. Vahedi H, Merat S, Rashidioon A, et al. The effect of fluoxetine in patients with pain and constipation-predominant irritable bowel syndrome: a double-blind randomized controlled study. Aliment Pharmacol Ther. 2005;22:381-385. (Pubitemid 41248104)
43. Kuiken SD, Tytgat GNJ, Boeckxstaens GEE. The selective serotonin reuptake inhibitor fluoxetine does not change rectal sensitivity and symptoms in patients with irritable bowel syndrome: a double-blind, randomized, placebo-controlled study. Clin Gastroenterol Hepatol. 2003;1:219-228. (Pubitemid 37248073)
44. Johanson JF, Drossman DA, Panas R, et al. Clinical trial: phase 2 study of lubiprostone for irritable bowel syndrome with constipation. Aliment Pharmacol Ther. 2008;27:685-696. (Pubitemid 351406304)
45. Drossman DA, Chey WD, Johanson JF, et al. Clinical trial: lubiprostone in patients with constipation-associated irritable bowel syndrome-results of two randomized placebo-controlled studies. Aliment Pharmacol Ther. 2008;29:329-341.
46. Agarwal N, Spiegel BM. The effect of irritable bowel syndrome on health-related quality of life and health care expenditure. Gastroenterol Clin North Am. 2011;40:11-19.